These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8390605)

  • 1. alpha-Bungarotoxin sensitization in experimental autoimmune myasthenia gravis.
    Kennel PF; Poindron P; Warter JM; Fonteneau P
    Muscle Nerve; 1993 May; 16(5):461-5. PubMed ID: 8390605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nerve stimulation test in murine experimental autoimmune myasthenia gravis.
    Pachner AR; Kantor FS
    Ann Neurol; 1982 Jan; 11(1):48-52. PubMed ID: 6277236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-fiber electromyography in experimental autoimmune myasthenia gravis.
    Verschuuren JJ; Spaans F; De Baets MH
    Muscle Nerve; 1990 Jun; 13(6):485-92. PubMed ID: 2366822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental autoimmune myasthenia gravis: can pretreatment with 125I-labeled receptor prevent functional damage at the neuromuscular junction?
    Sterz RK; Biro G; Rajki K; Filipp G; Peper K
    J Immunol; 1985 Feb; 134(2):841-6. PubMed ID: 2578165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of alpha-bungarotoxin binding to acetylcholine receptors by antisera from animals with experimental autoimmune myasthenia gravis.
    Claudio T; Raftery MA
    J Supramol Struct; 1980; 14(3):267-79. PubMed ID: 6971372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
    Zhang GX; Xiao BG; Bai XF; van der Meide PH; Orn A; Link H
    J Immunol; 1999 Apr; 162(7):3775-81. PubMed ID: 10201893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice.
    Berman PW; Heinemann SF
    J Immunol; 1984 Feb; 132(2):711-7. PubMed ID: 6690616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats.
    Qiao J; Wang ZY; Link H
    J Neurol Sci; 1994 Feb; 121(2):190-3. PubMed ID: 8158214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.
    Lindstrom JM; Einarson BL; Lennon VA; Seybold ME
    J Exp Med; 1976 Sep; 144(3):726-38. PubMed ID: 182896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. Acetylcholine receptor/cholinergic site/receptor function/autoimmunity.
    Mihovilovic M; Donnelly-Roberts D; Richman DP; Martinez-Carrion M
    J Immunol; 1994 Jun; 152(12):5997-6002. PubMed ID: 8207224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis.
    Krolick KA; Yeh TM; Edlund SA
    Cell Immunol; 1996 Aug; 172(1):10-20. PubMed ID: 8806801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological studies of acetylcholine receptors.
    Lindstrom J
    J Supramol Struct; 1976; 4(3):389-403. PubMed ID: 817087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models of myasthenia gravis.
    Christadoss P; Poussin M; Deng C
    Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Passive transfer of seronegative myasthenia gravis to mice.
    Burges J; Vincent A; Molenaar PC; Newsom-Davis J; Peers C; Wray D
    Muscle Nerve; 1994 Dec; 17(12):1393-400. PubMed ID: 7969240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis.
    Shenoy M; Baron S; Wu B; Goluszko E; Christadoss P
    J Immunol; 1995 Jun; 154(11):6203-8. PubMed ID: 7751658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to gallamine: an indicator of diminished neuromuscular function in experimental autoimmune myasthenia gravis.
    Hinman CL; Dambach GE; Hudson RA; Rauch HC
    J Neurosci Res; 1985; 14(2):271-8. PubMed ID: 4046075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental autoimmune myasthenia gravis in B10.BV8S2 transgenic mice: preferential usage of TCRAV1 gene by lymphocytes responding to acetylcholine receptor.
    Kaul R; Wu B; Goluszko E; Deng C; Dedhia V; Nabozny GH; David CS; Rimm IJ; Shenoy M; Haqqi TM; Christadoss P
    J Immunol; 1997 Jun; 158(12):6006-12. PubMed ID: 9190955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
    Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
    J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.